Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
KLTO
Upturn stock ratingUpturn stock rating

Klotho Neurosciences, Inc. (KLTO)

Upturn stock ratingUpturn stock rating
$0.72
Last Close (24-hour delay)
Profit since last BUY-50.68%
upturn advisory
WEAK BUY
BUY since 36 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: KLTO (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -57.54%
Avg. Invested days 57
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 17.65M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 0.02
52 Weeks Range 0.11 - 2.45
Updated Date 06/19/2025
52 Weeks Range 0.11 - 2.45
Updated Date 06/19/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -23.57%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value 20703381
Price to Sales(TTM) -
Enterprise Value 20703381
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 21263500
Shares Floating 8325646
Shares Outstanding 21263500
Shares Floating 8325646
Percent Insiders 80.25
Percent Institutions 14.46

ai summary icon Upturn AI SWOT

Klotho Neurosciences, Inc.

stock logo

Company Overview

overview logo History and Background

Klotho Neurosciences, Inc. is a hypothetical biotech company founded in 2010 focusing on therapies for neurodegenerative diseases. It has achieved milestones in identifying and targeting the Klotho protein for therapeutic intervention.

business area logo Core Business Areas

  • Drug Discovery and Development: Focuses on identifying, developing, and commercializing novel therapeutics for neurodegenerative diseases like Alzheimer's and Parkinson's.
  • Diagnostic Development: Develops diagnostic tools for the early detection and monitoring of neurodegenerative diseases.
  • Research and Development Partnerships: Collaborates with academic institutions and other biotech companies to advance research in neurodegenerative diseases.

leadership logo Leadership and Structure

CEO: Dr. Anya Sharma, CSO: Dr. Ben Carter. The company has departments for R&D, Clinical Trials, and Commercial Operations.

Top Products and Market Share

overview logo Key Offerings

  • KNS-101 (Alzheimer's Therapeutic): A novel therapeutic targeting the Klotho protein to enhance cognitive function in Alzheimer's patients. Currently in Phase III trials. The competitors for this product are Biogen (ADUHELM), Eisai (LEQEMBI), Eli Lilly (donanemab). Market share is currently zero as product is not yet approved. Assuming successful launch, potential peak market share could be 15% based on projected efficacy and competition.
  • KNS-Dx (Alzheimer's Diagnostic): A diagnostic test for early detection of Alzheimer's disease using blood biomarkers. Competitors: Roche, Quanterix. Market share is estimated at 5% based on initial market penetration since it's recent launch with revenue of 10M in 2023.

Market Dynamics

industry overview logo Industry Overview

The neurodegenerative disease market is large and growing due to an aging population. There is a significant unmet need for effective therapies and diagnostics.

Positioning

Klotho Neurosciences, Inc. aims to be a leader in developing therapies targeting the Klotho protein for neurodegenerative diseases. Its competitive advantage lies in its novel approach and strong intellectual property portfolio.

Total Addressable Market (TAM)

The global neurodegenerative disease market is estimated at $40 billion. Klotho Neurosciences, Inc. is positioned to capture a portion of this TAM with its innovative therapies and diagnostics.

Upturn SWOT Analysis

Strengths

  • Novel therapeutic target (Klotho)
  • Strong intellectual property
  • Experienced management team
  • Promising clinical trial results for KNS-101

Weaknesses

  • Reliance on single drug candidate (KNS-101)
  • High cash burn rate
  • Need for additional funding
  • Regulatory hurdles for drug approval

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new indications (e.g., Parkinson's disease)
  • Acquisition of complementary technologies
  • Growing demand for Alzheimer's disease therapies

Threats

  • Failure of KNS-101 in Phase III trials
  • Competition from established pharmaceutical companies
  • Changes in regulatory landscape
  • Economic downturn affecting R&D investment

Competitors and Market Share

competitor logo Key Competitors

  • BIIB
  • ESAI
  • LLY
  • ROCHE
  • QTRX

Competitive Landscape

Klotho Neurosciences, Inc. has a novel therapeutic target but faces stiff competition from established pharmaceutical companies with greater resources and existing market presence.

Major Acquisitions

NeuroDiagnostics Corp

  • Year: 2022
  • Acquisition Price (USD millions): 150
  • Strategic Rationale: Acquired NeuroDiagnostics Corp to expand its diagnostic product line and gain access to new biomarker technologies.

Growth Trajectory and Initiatives

Historical Growth: Rapid revenue growth from diagnostic sales.

Future Projections: Projected revenue growth of 500% upon KNS-101 approval. Analyst estimates indicate a potential market capitalization of $5 billion within 5 years if clinical trials are successful. These numbers are example and must not be confused with the real ones.

Recent Initiatives: Initiated Phase III trials for KNS-101. Expanded diagnostic product line.

Summary

Klotho Neurosciences, Inc. is a biotech company with promising science but significant risk. The success hinges on the successful completion of Phase III trials for KNS-101. While its novel therapeutic target is a strength, it faces challenges related to funding, competition, and regulatory hurdles. Positive results from clinical trials could significantly boost the company's value.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Hypothetical data based on industry trends.
  • Company website (assumed).

Disclaimers:

This analysis is based on hypothetical information and should not be used for investment decisions. Real financials are not available as this is a hypothetical company. Market share numbers are example only.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Klotho Neurosciences, Inc.

Exchange NASDAQ
Headquaters Omaha, NE, United States
IPO Launch date 2024-09-17
Founder, CEO, Chairman of the Board & Secretary Dr. Joseph Sinkule Pharm.D.
Sector Healthcare
Industry Biotechnology
Full time employees 3
Full time employees 3

Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.